Your browser doesn't support javascript.
loading
Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer.
Recondo, Gonzalo; Mezquita, Laura; Facchinetti, Francesco; Planchard, David; Gazzah, Anas; Bigot, Ludovic; Rizvi, Ahsan Z; Frias, Rosa L; Thiery, Jean Paul; Scoazec, Jean-Yves; Sourisseau, Tony; Howarth, Karen; Deas, Olivier; Samofalova, Dariia; Galissant, Justine; Tesson, Pauline; Braye, Floriane; Naltet, Charles; Lavaud, Pernelle; Mahjoubi, Linda; Abou Lovergne, Aurélie; Vassal, Gilles; Bahleda, Rastilav; Hollebecque, Antoine; Nicotra, Claudio; Ngo-Camus, Maud; Michiels, Stefan; Lacroix, Ludovic; Richon, Catherine; Auger, Nathalie; De Baere, Thierry; Tselikas, Lambros; Solary, Eric; Angevin, Eric; Eggermont, Alexander M; Andre, Fabrice; Massard, Christophe; Olaussen, Ken A; Soria, Jean-Charles; Besse, Benjamin; Friboulet, Luc.
Afiliação
  • Recondo G; INSERM U981, Gustave Roussy Cancer Campus, Villejuif, France.
  • Mezquita L; Université Paris-Saclay, Paris, France.
  • Facchinetti F; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.
  • Planchard D; INSERM U981, Gustave Roussy Cancer Campus, Villejuif, France.
  • Gazzah A; Université Paris-Saclay, Paris, France.
  • Bigot L; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.
  • Rizvi AZ; Drug Development Department (DITEP), Gustave Roussy Cancer Campus, Villejuif, France.
  • Frias RL; INSERM U981, Gustave Roussy Cancer Campus, Villejuif, France.
  • Thiery JP; Université Paris-Saclay, Paris, France.
  • Scoazec JY; INSERM U981, Gustave Roussy Cancer Campus, Villejuif, France.
  • Sourisseau T; Université Paris-Saclay, Paris, France.
  • Howarth K; INSERM U981, Gustave Roussy Cancer Campus, Villejuif, France.
  • Deas O; Université Paris-Saclay, Paris, France.
  • Samofalova D; Yong Loo Lin School of Medicine, National University of Singapore, Republic of Singapore.
  • Galissant J; Institute of Biomedicine and Health, Chinese Academy of Science, Beijing, P.R. China.
  • Tesson P; CCBIO, Department of Clinical Medicine, Faculty of Medicine and Dentistry, The University of Bergen, Bergen, Norway.
  • Braye F; Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, Hong Kong University, Hong Kong.
  • Naltet C; CNRS UMR 7057 Matter and Complex Systems, University Paris Denis Diderot, Paris, France.
  • Lavaud P; Université Paris-Saclay, Paris, France.
  • Mahjoubi L; Experimental and Translational Pathology Platform (PETRA), Genomic Platform-Molecular Biopathology Unit (BMO) and Biological Resource Center, AMMICA, INSERM US23/CNRS UMS3655, Gustave Roussy Cancer Campus, Villejuif, France.
  • Abou Lovergne A; Department of Medical Biology and Pathology, Gustave Roussy Cancer Campus, Villejuif, France.
  • Vassal G; INSERM U981, Gustave Roussy Cancer Campus, Villejuif, France.
  • Bahleda R; Université Paris-Saclay, Paris, France.
  • Hollebecque A; Inivata, Granta Park, United Kingdom.
  • Nicotra C; XenTech, Evry, France.
  • Ngo-Camus M; Life Chemicals Inc., Ontario, Canada.
  • Michiels S; Institute of Food Biotechnology and Genomics NAS of Ukraine, Kyiv, Ukraine.
  • Lacroix L; INSERM U981, Gustave Roussy Cancer Campus, Villejuif, France.
  • Richon C; Université Paris-Saclay, Paris, France.
  • Auger N; INSERM U981, Gustave Roussy Cancer Campus, Villejuif, France.
  • De Baere T; Université Paris-Saclay, Paris, France.
  • Tselikas L; INSERM U981, Gustave Roussy Cancer Campus, Villejuif, France.
  • Solary E; Université Paris-Saclay, Paris, France.
  • Angevin E; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.
  • Eggermont AM; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.
  • Andre F; Drug Development Department (DITEP), Gustave Roussy Cancer Campus, Villejuif, France.
  • Massard C; Université Paris-Saclay, Paris, France.
  • Olaussen KA; Department of Clinical Research, Gustave Roussy Cancer Campus, Villejuif, France.
  • Soria JC; Department of Clinical Research, Gustave Roussy Cancer Campus, Villejuif, France.
  • Besse B; Drug Development Department (DITEP), Gustave Roussy Cancer Campus, Villejuif, France.
  • Friboulet L; Drug Development Department (DITEP), Gustave Roussy Cancer Campus, Villejuif, France.
Clin Cancer Res ; 26(1): 242-255, 2020 01 01.
Article em En | MEDLINE | ID: mdl-31585938
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Lactamas Macrocíclicas / Quinase do Linfoma Anaplásico / Neoplasias Pulmonares Tipo de estudo: Observational_studies Limite: Adult / Animals / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article País de afiliação: França
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Lactamas Macrocíclicas / Quinase do Linfoma Anaplásico / Neoplasias Pulmonares Tipo de estudo: Observational_studies Limite: Adult / Animals / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article País de afiliação: França